Funding for this research was provided by:
National Natural Science Foundation of China (81760424)
Received: 3 July 2020
Accepted: 2 June 2021
First Online: 8 June 2021
: The research was approved by Medical Ethics Committee of Guangxi Medical University (Approval No: 20170228–31). As this retrospective study used deidentified residual tumor specimens with no personally private information, a waiver of informed consent to participate is granted by the Medical Ethics Committee according to Chapter IV Rule #34 from ‘Measures for the Ethical Review of Biomedical Research Involving Human Subjects’ by the National Health and Family Planning Commission of China.
: Not applicable.
: The authors declare that they have no competing interests.